Octreotide (long-acting release formulation) treatment in patients with Graves' Orbitopathy: Clinical results of a four-month, randomized, placebo-controlled, double-blind study

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 841-848

  Wemeau J L ^a   Caron, P ^b   Beckers, A ^c   Rohmer, V ^d   Orgiazzi, J ^e   Borson Chazot, F ^e   Nocaudie, M ^a   Perimenis, P ^a   Bisot Locard, S ^f   Bourdeix, I ^f   Dejager, S ^f  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b CHU RANGUEIL   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTITHYROID AGENT; ARTIFICIAL TEAR; BENZYLTHIOURACIL; CARBIMAZOLE; GLUCOCORTICOID; INDIUM; IODINE 131; LUBRICATING AGENT; OCTREOTIDE; PENTETREOTIDE IN 111; PLACEBO; PROPYLTHIOURACIL; SOMATOSTATIN DERIVATIVE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ACTIVITY SCALE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DISEASE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; ENDOCRINE OPHTHALMOPATHY; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYELID; FEMALE; GASTROINTESTINAL SYMPTOM; GAZE; HUMAN; ISOTOPE LABELING; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MULTICENTER STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORBIT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME;

DELAYED-ACTION PREPARATIONS; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; GRAVES DISEASE; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PLACEBOS; TIME FACTORS;

EID: 20044390208     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1334     Document Type: Article

References (47)

1. Burch HB, Wartofsky L 1993 Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 14:747-793
2. Prabhakar BS, Bahn RS, Smith TJ 2003 Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 24:802-835
3. Bahn RS 2003 Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 88:1939-1946
4. Amino N, Yuasa T, Yabu Y, Miyai K, Kumahara Y 1980 Exophthalmos in autoimmune thyroid disease. J Clin Endocrinol Metab 51:1232-1234
5. Werner SC, Coleman DJ, Franzen LA 1974 Ultrasonographic evidence of a consistent orbital involvement in Graves's disease. N Engl J Med 290:1447-1450
6. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF 2000 Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 52:267-271
7. Wiersinga WM, Prummel MF 2001 Pathogenesis of Graves' ophthalmopathy: current understanding. J Clin Endocrinol Metab 86:501-503
8. Ludgate M, Baker G 2002 Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol 127:193-198
9. Bahn RS, Heufelder AE 1993 Pathogenesis of Graves' ophthalmopathy. N Engl J Med 329:1468-1475
10. Gorman CA 1991 Clever is not enough: NOSPECS is form in search of function. Thyroid 1:353-355
11. Mounts MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, Van der GR 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 73:639-644
12. Perros P, Kendall-Taylor P 2002 Medical treatment for thyroid-associated ophthalmopathy. Thyroid 12:241-244
13. Krassas GE, Heufelder AE 2001 Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 144: 311-318
14. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM 1993 Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 342:949-954
15. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov 2:999-1017
16. Pasquali D, Vassallo P, Esposito D, Bonavolonta G, Bellastella A, Sinisi AA 2000 Somatostatin receptor gene expression and inhibitory effects of octreoride on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 25:63-71
17. Pasquali D, Notaro A, Bonavolontá G, Vassallo P, Bellastella A, Sinisi AA 2002 Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 87:5125-5129
18. Krassas GE 1998 Somatostatin analogues in the treatment of thyroid eye disease. Thyroid 8:443-445
19. Krassas GE, Pontikides N, Kaltsas T, Dumas A, Frystyk J, Chen JW, Flyvbjerg A 2003 Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab 88:132-135
20. Krassas G, Kaltsas T, Pontikides N, Dumas A 1997 Somatostatin therapy and Graves' ophthalmopathy. Thyroid 7:489
21. Krassas GE, Doumas A, Kaltsas T, Halkias A, Pontikides N 1999 Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease. Thyroid 9:47-52
22. Kung AW, Michon J, Tai KS, Chan FL 1996 The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid 6:381-384
23. Uysal AR, Corapcioglu D, Tonyukuk VC, Gullu S, Sav H, Kamel N, Erdogan G 1999 Effect of octreotide treatment on Graves' ophthalmopathy. Endocr J 46:573-577
24. Ozata M, Bolu E, Sengul A, Tasar M, Beyhan Z, Corakci A, Gundogan MA 1996 Effects of octreotide treatment on Graves' ophthalmopathy and circulating sICAM-1 levels. Thyroid 6:283-288
25. Perros P, Crombie AL, Kendall-Taylor P 1995 Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 42:45-50
26. Leplege A, Ecosse E, Verdier A, Perneger TV 1998 The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation. J Clin Epidemiol 51:1013-1023
27. Terwee CB, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, Wiersinga WM 1999 Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves' ophthalmopathy. J Clin Epidemiol 52:875-884
28. Forster GJ, Krummenauer F, Nickel O, Kahaly GJ 2000 Somatostatin-receptor scintigraphy in Graves' disease: reproducibility and variance of orbital activity. Cancer Biother Radiopharm 15:517-525
29. Nocaudie M, Bailliez A, Itti E, Bauters C, Wemeau JL, Marchandise X 1999 Somatostatin receptor scintigraphy to predict the clinical evolution and therapeutic response of thyroid-associated ophthalmopathy. Eur J Nucl Med 26: 511-517
30. Gerding MN, van der Zant FM, van Royen EA, Koornneef L, Krenning EP, Wiersinga WM, Prummel MF 1999 Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 50:373-379
31. 111In-DTPA-D- Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity? J Clin Endocrinol Metab 79:1845-1851
32. 111In-octreotide. Thyroid 7:21-29
33. Firbank MJ, Harrison RM, Williams ED, Coulthard A 2001 Measuring extraocular muscle volume using dynamic contours. Magn Reson Imaging 19:257-265
34. Hiromatsu Y, Kojima K, Ishisaka N, Tanaka K, Sato M, Nonaka K, Nishimura H, Nishida H 1992 Role of magnetic resonance imaging in thyroid-associated ophthalmopathy: its predictive value for therapeutic outcome of immunosuppressive therapy. Thyroid 2:299-305
35. Markl AF, Hilbertz T, Mann K 1989 Graves' ophthalmopathy: standardized evaluation of computed tomography examinations; magnetic resonance imaging. Dev Ophthalmol 20:38-50
36. Prummel MF, Wiersinga WM 1993 Smoking and risk of Graves' disease. JAMA 269:479-482
37. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchers A 1998 Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 129:632-635
38. Wiersinga WM, Bartalena L 2002 Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 12:855-860
39. Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168-199
40. Gelding MN, Prummel MF, Wiersinga WM 2000 Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters. Clin Endocrinol (Oxf) 52:641-646
41. 99mTc-EDDA/HYNIC-TOC in Graves' disease. Eur J Nucl Med Mol Imaging 29:1267
42. 111In-diethylenetriamine pentaacetic acid-D-phe1]-octreotide predicts the clinical response to corticosteroid therapy in patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 83:3790-3794
43. Loos U, Raptis S, Birk J, Escobar-Jimenez F, Meyer G, Rothenbuchner G, Pfeiffer EF 1978 Inhibition of TSH-stimulated radioiodine turnover and release of T4 and T3 in vivo by somatostatin. Metabolism 27:1269-1273
44. Bland JM, Altman DG 1995 Multiple significance tests: the Bonferroni method. BMJ 310:170
45. Kendall-Taylor, Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baster E, Andrews C, Hesse L, Heverhagen J, Heufelder AE 2003 Double-blind placebo-controlled trial of octreotide LAR in thyroid-associated orbitopathy (TAO): clinical outcome. Thyroid 13:671 (Abstract)
46. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716
47. Prummel MF, Bakker A, Wiersinga WM, Baldeschi L, Mourits MP, Kendall-Taylor P, Perros P, Neoh C, Dickinson AJ, Lazarus JH, Lane CM, Heufelder AE, Kahaly GJ, Pitz S, Orgiazzi J, Hullo A, Pinchera A, Marcocci C, Sartini MS, Rocchi R, Nardi M, Krassas GE, Halkias A 2003 Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy Experience. Eur J Endocrinol 148:491-495